Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02075281 · ClinicalTrials.gov registry record · Phase 2
Effect of LAPS-Exendin on Body Weight in Obese Population
A Phase 2 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 297
- Enrollment target
NCT02075281: Completed Phase 2 study, sponsored by Hanmi Pharmaceutical Company Limited.
NCT02075281 is a Phase 2 study that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 297 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (123% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02075281, a Phase 2 study, has completed, sponsored by Hanmi Pharmaceutical Company Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 297 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL HM11260C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
What the finished NCT02075281 record still lists
NCT02075281 is an interventional study that assigns participants to a tested intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (123% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02075281 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02075281 about?
NCT02075281 is a clinical study titled "Effect of LAPS-Exendin on Body Weight in Obese Population". The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.
What is the current status of trial NCT02075281?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 297 participants. The study started on 2014-02. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02075281?
The interventions under investigation include: Placebo (BIOLOGICAL), HM11260C (BIOLOGICAL).
Who is sponsoring clinical trial NCT02075281?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02075281's enrollment target sits among peer trials
297 188th of 2000 higher than 1,812 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
- NCT06375811 · 297 participants · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
- NCT07222215 · 297 participants · Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia